Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

RBM39 degrader REC-1245

An orally bioavailable molecular glue degrader of the splicing factor RNA-binding protein 39 (RNA-binding motif protein 39; RBM39), with potential antineoplastic activity. Upon oral administration, RBM39 degrader REC-1245 induces the ubiquitination and proteasome-mediated degradation of RBM39 via the E3 ligase adaptor DCAF15. This modulates RNA splicing, prevents the expression of certain tumor-associated genes, and downregulates DNA damage response (DDR) networks and cell cycle checkpoints including cyclin-dependent kinase 12 (CDK12), which may inhibit tumor cell proliferation. RBM39, overexpressed in many cancers, plays an important role in alternative splicing and regulating the transcription of many tumor-related genes.
Synonym:RBM39 molecular glue degrader REC-1245
Code name:REC 1245
REC-1245
REC1245
Search NCI's Drug Dictionary